Non-alcoholic steatohepatitis (NASH): Approaching more tailored and effective therapies

Journal of Gastrointestinal and Liver Diseases

Volumn 16, Issue 2, 2007, Pages 167-169

  Portincasa, Piero ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; LOSARTAN; PENTOXIFYLLINE; PLACEBO; PRAVASTATIN; URSODEOXYCHOLIC ACID;

BARIATRIC SURGERY; BREATH ANALYSIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MEGADOSE; DYSLIPIDEMIA; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER HISTOLOGY; LIVER INJURY; LOW DRUG DOSE; MEDICAL RESEARCH; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; OBESITY; STOICHIOMETRY;

COENZYME A LIGASES; FATTY LIVER; HUMANS;

EID: 34347329340     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006;136:3022-3026.
3. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. The emerging problem of nonalcoholic steatohepatitis (NASH). Rom J Gastroenterol 2005;14:43-51.
4. Portincasa P, Wallner G, Krawczyc M, Ciechanski A, Maciejewski R. Wspolczesne poglady na temat patofizjologii, diagnozowania i leczenia niealkoholowego stluszczeniowego zapalenia watroby (Current opinions on pathophysiology, diagnosis and treatment of nonalcoholic steatohepatitis). Gastroenterologia Polska 2006;13:501-506.
5. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007;16:39-46.
6. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996;80:1147-1166.
7. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Non-alcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem 2005;38:203-217.
8. Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006;111:135-143.
9. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006;13:2889-2900.
10. Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130:1564-1572.
11. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23:131-134.
12. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-718.
13. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193-196.
14. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222-1225.
15. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994;83:262-267.
16. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-2368.
17. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-1467.
18. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-778.
19. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537-1543.
20. Yakaryilmaz F, Guliter S, Savas B, et al. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007;37:229-235.
21. Guallar E, Hanley DF, Miller ER, III. An editorial update: Annus horribilis for vitamin E. Ann Intern Med 2005;143:143-145.
22. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-130.
23. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-190.